Actinogen Medical Limited will present at the BIO International Convention, to be held at the Boston Convention & Exhibition Center from June 5-8, 2023. The Actinogen presentation is scheduled at 4pm EST June 5, 2023, in Room 403. Dr. Gourlay and Dr. Hilt will be discussing progress made with the Company's two ongoing Phase 2 trials: XanaCIDD Phase 2a trial of cognitive impairment in major depressive disorder This Phase 2a, proof-of-concept trial commenced in December 2022 and will treat 160 patients with Major Depressive Disorder (MDD) who also have cognitive impairment.

Cognitive impairment is common in MDD and currently there are no anti-depressant drugs approved for its treatment, although some companies have reported trials to assess effects of their anti-depressants on cognition. Consequently, there is a high unmet need for novel and safe treatments for this indication. The trial is being conducted in Australia and the UK and will treat patients with 10 mg of Xanamem or placebo once daily for six weeks as monotherapy or added to stable background anti-depressant therapy.

The primary endpoint is an attention composite of three computerized cognitive tests measuring attention and working memory. Depression is assessed as a key secondary endpoint using the MADRS scale. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases.

The cognitive function, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments. About Xanamem Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon allowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease and excess cortisol is known to be toxic to brain cells. Cognitive impairment is also a feature in Depression and many other diseases. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials.

The company has studied 11-HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in functional and cognitive ability in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterize Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem(R) is a trademark of Actinogen Medical.